Physician profile
Michael A Valente
NPI 1265492078
$184,193.45
in general payments reported to CMS, 2019-2025
57 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $23K · 2021: $35K · 2022: $49K · 2023: $15K · 2024: $21K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $8,602 · Travel and Lodging: $2,772 · Consulting Fee: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,537.50 |
| Food and Beverage | $8,602.07 |
| Travel and Lodging | $2,772.30 |
| Consulting Fee | $1,525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $88,730.71 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $43,421.36 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $15,627.57 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14,323.83 | 2022 | |
| Mdd US Operations, LLC | $12,659.88 | 2019-2025 | Gocovri, Gocovri |
| Pfizer INC. | $1,908.17 | 2023-2025 | |
| Ucb, INC. | $605.44 | 2023-2025 | Briviact, Rystiggo, Fintepla |
| Biogen, INC. | $584.31 | 2019-2025 | Tysabri, Vumerity, Spinraza |
| Celgene Corporation | $512.28 | 2023-2025 | Zeposia |
| Lilly USA, LLC | $474.76 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $456.02 | 2019-2025 | |
| Lundbeck LLC | $426.06 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $341.56 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $339.80 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Argenx US, INC. | $296.18 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $281.78 | 2022-2025 | |
| Genentech USA, INC. | $260.22 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Alexion Pharmaceuticals, INC. | $222.86 | 2019-2025 | Ultomiris |
| Merz North America, INC. | $208.39 | 2019-2020 | |
| Amgen INC. | $172.90 | 2020-2023 | Aimovig |
| Genzyme Corporation | $172.68 | 2019-2021 | |
| Emd Serono, INC. | $168.84 | 2022-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $129.70 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $123.23 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $120.52 | 2024-2025 | Xeomin, Inbrija |
| Mallinckrodt Hospital Products INC. | $118.14 | 2024-2025 | Acthar |
| Kyowa Kirin, INC. | $116.71 | 2019-2024 | Nourianz |
| Neurelis, INC. | $97.23 | 2022-2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $96.79 | 2024-2025 | Wainua |
| Neurocrine Biosciences, INC. | $87.05 | 2019-2024 | Ingrezza, Ongentys |
| Csl Behring | $82.88 | 2022-2025 | Hizentra |
| Livanova USA, INC. | $79.47 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sumitomo Pharma America, INC. | $76.59 | 2023-2024 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $76.20 | 2023-2025 | Rexulti, Nuedexta |
| Acorda Therapeutics, INC | $71.99 | 2019-2023 | Inbrija |
| E.R. Squibb & Sons, L.L.C. | $65.33 | 2023-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $61.09 | 2023-2025 | Austedo Xr, Austedo Xr |
| Ani Pharmaceuticals, INC. | $55.95 | 2025 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $54.93 | 2019-2025 | Qelbree |
| Acadia Pharmaceuticals INC | $43.02 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $41.01 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $36.69 | 2025 | Ponvory |
| Impel Pharmaceuticals INC. | $35.17 | 2022-2023 | Trudhesa |
| Greenwich Biosciences, INC. | $34.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $34.44 | 2019-2022 | |
| Medtronic, INC. | $34.41 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $29.89 | 2024 | |
| Sunovion Pharmaceuticals INC. | $27.15 | 2020 | |
| Grifols USA, LLC | $23.36 | 2023 | Gamunex-C |
| Springworks Therapeutics, INC. | $22.53 | 2025 | Gomekli |
| Alnylam Pharmaceuticals INC. | $21.97 | 2025 | Onpattro |
| Ethicon US, LLC | $21.25 | 2025 | Contour |
| Avion Pharmaceuticals | $19.87 | 2022 | |
| Boston Scientific Corporation | $17.13 | 2019 | |
| Microtransponder, INC. | $15.32 | 2025 | |
| Corium, LLC | $14.32 | 2023 | Adlarity |
| Upsher-Smith Laboratories LLC | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Valente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.